Calliditas Therapeutics CALT
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
If exposure is desired: consider the parent company Asahi Kasei (3407 JP) instead.
The company is delisted and operates as a subsidiary of Asahi Kasei, making direct exposure via CALT impossible and shifting focus to the parent's execution and pipeline data.
Sentiment remains cautiously positive around TARPEYO's commercial potential, but discussion has declined post-delisting with focus shifting to pipeline data and Asahi Kasei execution.
NEUTRAL is the call. Neutral is the market mood. Medium risk means some things can go wrong.
About the company
Calliditas Therapeutics is a biopharma company focused on rare kidney diseases, with the commercial product TARPEYO/Kinpeygo (delayed-release budesonide) for IgA nephropathy. The company was acquired by Asahi Kasei in 2024 and delisted from Nasdaq Stockholm, meaning reporting and tradability may be limited or consolidated into the parent company.
Bull case
Strong commercial traction for TARPEYO after full approvals combined with Asahi Kasei support can improve execution and pipeline valuation.
Bear case
Delisting reduces transparency, increased competition from Fabhalta and Ultomiris may pressure growth, and clinical risks remain in the setanaxib program.
Why this signal
The company is delisted and operates as a subsidiary of Asahi Kasei, making direct exposure via CALT impossible and shifting focus to the parent's execution and pipeline data.
Recent news
No new press releases, news articles or company-specific events have been reported after 2026-11-10. The company is a subsidiary of Asahi Kasei following the 2026 acquisition.